Special Report: Inside the battle for Genzyme's future

Special Report: Inside the battle for Genzyme's future

posted in: Science by dyarter On May 12th, 2010

BOSTON (Reuters) – At a recent dinner to honor the achievements of Henri Termeer, chief executive of biotechnology company Genzyme, Ananth Raman broke down as he recalled the moment he learned his 7-month old daughter had Pompe disease, a rare genetic disorder that was damaging her heart. It was 2005 and doctors told him there was no cure. His child, they said, probably had less than five months to live.


Original post here Reuters: Science News

For hot penny stock picks, daily small cap alerts, and stock market news alerts visit http://www.stockorange.com

No Responses to “Special Report: Inside the battle for Genzyme's future”

Leave a Reply

About Us

StockOrange is a cutting edge awareness newsletter specifically focused on the audience interested in compelling microcap and smallcap equities. The Companies that align with us are looking to solidify their brand among potential investors, expand their base, and dominate the competitive landscape. We leverage both innovative and traditional awareness strategies with getting your Company’s story to our community, while providing readers relevant market news and current global affairs. We can also help your Company develop a news strategy necessary to rise above the general market clamor.

Learn More About Us

What We Do

StockOrange has a specific philosophy and method to selecting and generating awareness campaigns. We proactively communicate to our community beyond the news from the Company (shareholder calls, issuing news, respond to investors, etc.). We can certainly handle those responsibilities, but we strategically take it to the next level with value added resources and information financially savvy readers are looking for (market news and commentaries, trade alerts, global current affairs, etc.).

Learn About Our Services

Get Fresh Picks Delivered Sign Up For Our Free Newsletter Today!